EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation

Zaynab Somani iD, James S Hodges iD, Srinath Chinnakotla iD, David Martin, Karthik Ramanathan iD, Gregory J Beilman iD, Melena D Bellin iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Zaynab Somani und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Pancreatectomy, Islets of Langerhans Transplantation, Blood Glucose, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Targets for continuous glucose monitoring (CGM) are well established for type 1 and type 2 diabetes. In total pancreatectomy with islet autotransplantation (TPIAT), stricter glycemic targets are needed to avoid metabolic stress on transplanted islets, but no guidelines exist for CGM targets.

Methods

We aimed to determine CGM targets for TPIAT clinical management by associating CGM metrics with goal hemoglobin A1c (HbA1c) ≤ 6.5%. Targets for time in range (TIR) 70–140, TIR 70–180, mean CGM glucose, and time in hyperglycemia (>140, >180, >250 mg/dL) were chosen to give good sensitivity and specificity for identifying HbA1c ≤6.5%.

Results

We included 256 pairs of 14‐day CGM metrics with a concurrent HbA1c value ( n = 82 patients, age 35 [IQR 19–46] years at surgery, 70% female) who were ≥0.5 years post TPIAT (median 4.1 years) and wearing Dexcom G6. Most patients had more than one HbA1c and corresponding CGM available (median 2 [IQR 1–4] per patient).

Conclusion

We found that TIR 70–140 ≥ 50% and TIR 70–180 mg/dL ≥ 75% may be reasonable minimum targets for patients and providers using CGM data to manage diabetes long‐term after TPIAT. Failure to meet these targets should prompt starting or adjusting insulin therapy, especially if hypoglycemia is not a concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PancreatectomyIslets of Langerhans TransplantationBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1BiomarkersDiabetes Mellitus, Type 2HyperglycemiaHumansFemaleMaleMiddle AgedAdultFollow-Up StudiesTransplantation, AutologousPrognosisYoung AdultGlycated HemoglobinRetrospective StudiesContinuous Glucose Monitoring

Stichwörter der Autor:innen

autologousblood glucoseclinical targetscontinuous glucose monitoring (CGM)diabetesglycated hemoglobinpancreatectomytotal pancreatectomy with islet autotransplantation (TPIAT)transplantation

Substanzen

Blood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanBiomarkers

Autor:innen und Institutionen

  • University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Critical Care & Acute Care Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID-Profile: Zaynab Somani, James S Hodges, Srinath Chinnakotla, Karthik Ramanathan, Gregory J Beilman, Melena D Bellin

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Somani, Z., Hodges, J. S., Chinnakotla, S., Martin, D., Ramanathan, K., Beilman, G. J., & Bellin, M. D. (2025). Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70202

Vancouver

Somani Z, Hodges JS, Chinnakotla S, Martin D, Ramanathan K, Beilman GJ, et al. Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70202

BibTeX
@article{Somani2025,
  author = {Somani, Zaynab and Hodges, James S and Chinnakotla, Srinath and Martin, David and Ramanathan, Karthik and Beilman, Gregory J and Bellin, Melena D},
  title = {Defining Targets for Continuous Glucose Monitoring After Total Pancreatectomy With Islet Autotransplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70202}
}
Kostenlos starten →